Insider Buying: Oxford Biomedica (LON:OXB) Insider Acquires 6,175 Shares of Stock

Key Points

• Heather Preston, an insider at Oxford Biomedica, purchased 6,175 shares at an average price of GBX 593, totaling approximately £36,617.75.
• Oxford Biomedica's stock saw a decline of 2.5%, trading at GBX 575, with a market cap of £691.18 million.
• Analysts have mixed ratings on the stock, with price targets ranging from GBX 400 to GBX 930, reflecting a consensus rating of "Moderate Buy."

Oxford Biomedica plc (LON:OXB - Get Free Report) insider Heather Preston purchased 6,175 shares of the company's stock in a transaction that occurred on Monday, October 20th. The shares were bought at an average cost of GBX 593 per share, with a total value of £36,617.75.

Oxford Biomedica Trading Down 2.5%

OXB traded down GBX 14.79 during trading on Monday, hitting GBX 575. 231,466 shares of the company's stock were exchanged, compared to its average volume of 272,951. The firm has a market cap of £691.18 million, a P/E ratio of -15.88 and a beta of 1.09. The stock has a 50 day moving average price of GBX 569.53 and a 200 day moving average price of GBX 413.36. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. Oxford Biomedica plc has a 1 year low of GBX 232.50 and a 1 year high of GBX 660.

Analysts Set New Price Targets

OXB has been the topic of a number of recent research reports. JPMorgan Chase & Co. reduced their price target on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Royal Bank Of Canada raised their target price on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the company an "outperform" rating in a research note on Tuesday, August 26th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a research note on Tuesday, October 7th. Finally, Peel Hunt reaffirmed a "buy" rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a research note on Friday, August 1st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Oxford Biomedica presently has a consensus rating of "Moderate Buy" and an average target price of GBX 558.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.